John Leonard, MD, discusses the number of options doctors have to choose from when treating follicular lymphomas.
John Leonard, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses the number of options doctors have to choose from when treating follicular lymphomas. Leonard says some of the more common and older options for these patients are the anti-CD20 antibody rituximab and bendamustine, with the latter being used especially if the patient had not previously received it in combination with rituximab.
Leonard says in addition to those treatments, the anti-body obinutuzumab has also been approved in patients with rituximab refractory relapsed follicular lymphoma. Data for idelalisib, a PI3 kinase inhibitor that can work in rituximab refractory patients, and RCHOP chemotherapy is another option, are also viable options, according to Leonard.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More